CTOs on the Move

Uroplasty

www.uroplasty.com

 
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Light Sciences Oncology

Light Sciences Oncology Inc. is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Levitee Labs

Levitee Labs is a multidisciplinary integrative wellness company dedicated to redefining traditional mental health and addiction treatments through integrating evidence-based complementary medicines and novel psychedelic therapies into the traditional infrastructure of mental health treatment.

Lee Pharmaceuticals

Lee Pharmaceuticals is an established manufacturer of quality lip balm, saline nasal spray and OTC products. We are aggressively pursuing the Private Label Lip Balm and OTC business with our products that are national brand equivalent.

inVentiv Medical Management

inVentiv Medical Management is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.